About
Sativa therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
2
As Collaborator
2
Total Enrollment
275
By Phase
PHASE1: 2PHASE2: 2
By Status
RECRUITING: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06563375Collaborator
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
PHASE1Recruiting
35 participants
Started: Mar 5, 2025 · Completed: Sep 1, 2030
NCT05785390Lead Sponsor
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
PHASE2Terminated
170 participants
Started: Feb 22, 2023 · Completed: May 9, 2025
NCT05262556Collaborator
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
PHASE1Active, not recruiting
15 participants
Started: Dec 15, 2022 · Completed: Jun 30, 2026
NCT04914377Lead Sponsor
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
PHASE2Completed
55 participants
Started: Jun 8, 2021 · Completed: Jan 1, 2022
Locations (1)
Headquarters
Pearland, TX, United States
Map
Loading map...